Contact

Selected Testimonials

Our aim is to meet or exceed our customers’ expectations. Have a look at the testimonials below and let us convince you of the high quality of our products and services.

PepTrack™ Peptide Libraries

 “My group at the Virology Department of the UK Animal Health and Veterinary Laboratories Agency focuses on defining the T cell target antigens of important veterinary viral pathogens and the exploitation of this information in the development of new/improved vaccines. Our need for economic whole viral proteome spanning peptide libraries led us to JPT's PepTrack™ Peptide Libraries. The sensitivity of our cellular assays towards cytotoxic contaminants as well as impurities yielding in unwanted T-cell stimulation prompted a systematic evaluation of peptide sources. JPT turned out to be the most reliable vendor regarding both delivery time and high quality levels based on a certified Quality Management System. I am collaborating with JPT for many years and certainly recommend their services.”
Simon Graham, PhD (Virology Department of the UK Animal Health and Veterinary Laboratories Agency, Addlestone, Surrey, UK

"I have been collaborating with JPT for several years. Their unique peptide library technologies and knowledge of specific peptide requirements for T-cell assays made them a valuable, long-term partner in our efforts to develop novel adoptive immunotherapy approaches to prevent and treat viral infections post-transplant as well as for the treatment of virus and non virus-associated malignancies. Furthermore, their reagents allow us to precisely monitor and track specific T cell populations post-infusion"
Ann Leen, PhD (Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA)

“We utilize JPT’s peptide libraries and pools for T-cell epitope mapping and immune monitoring applications such as ELISPOT and ICS, as well as CFC. The combination of synthesis economy, quick turnaround time and tailored specifications are key to our success. JPT’s scientific competence is invaluable for all institutions planning to employ peptides in immuno assays for research or clinical setups."
Johannes Hampl, PhD (Anza Therapeutics, Inc, Concord, CA, USA)

PepMix™ Peptide Pools

"To establish a novel role for myeloid derived suppressor cells (Pallett et al, Nat. Med. 2015) in chronic viral infection, we utilised the PepMix CEF Pool (extended) as well as a custom synthesized PepMix spanning the core region of HBV genotype D .  Whereas, the CEF peptide pool consists of 32 peptides, each corresponding to a defined HLA class I-restricted T-cell epitope from Cytomegalo, Epstein-Barr, and Influenza virus, the latter custom PepMix included 15meric peptides overlapping by 10 amino acids.  Specifically this composition enabled us to monitor both the antiviral CD8+ and CD4+ T cell responses in chronic HBV infection and the non-antigen specific T cells that are known to mediate immunopathology in the liver. Our entire experience with JPT, from ordering/delivery to use in the lab was excellent. Not only were the reagents able to perform reliably and consistently in vitro from batch to batch, the customer and technical support provided was continually available and efficient when needed. JPT will remain our "go-to" company for purchasing peptides."
Dr Laura J Pallett, Infection and Immunity, University College London, UK.

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen (Charité Berlin, Berlin, Germany)

"The focus of the Clinical Immunology Group at the German Rheumatism Research Centre is to study the role of cells and molecules in the origin and progression of autoimmune and other diseases. In our hands PepMixes™ were found to be effective in monitoring the immune status of various patient populations but show also promise for the development of novel immuno therapy approaches." 
Dr. Andreas Thiel (German Rheumatism Research Centre, Clinical Immunology, Berlin, Germany)

"I have used JPT's peptide pools (PepMix™) for years now, with great satisfaction! (First CMV derived peptides and now also EBV.) So far we have published data in one publication and plan several more in the near future."
Ms. Anna Karin Lidehäll (Uppsala University, Dept. of Clinical Immunology, Uppsala, Sweden)

GxP Peptides & Pools

"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA 

"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines.  Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service.  JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations." 
Benedetto Farsaci, MD, National Cancer Institute, NIH, Bethesda, MD, USA 

"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for  adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized  PepMix™Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency.”
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada

PepStar™ Peptide Microarrays

"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT's PepStar™ microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!"
J. Currier, PhD (Walter Reed Army Institute, Rockville, Maryland, USA)

"Carolus’ technology enabled the development of therapeutic peptides and antibodies that target specific interactions between macrophage migration inhibiting factor and its chemokine receptors as well as RANTES and platelet factor-4. JPT's PepStar™ peptide microarray platform as well as its full profiling service and data interpretation capabilities have been a reliable and robust approach to elucidate the molecular details of these protein- protein interactions."

Dr. Joshua Schultz (Carolus Therapeutics, Inc., San Diego, CA, USA)

"Over the past five years my research team has been active in the development of species-specific peptide arrays. Our ability to advance this technology into new research areas has been dependent on working with the highest quality of arrays. In this regard, JPT’s commitment to excellence has been a critical foundation for the success of our research program.  I have been consistently impressed with their customer service, technical expertise and professionalism. When it comes to peptide work there are no other options for our group…JPT is the best."
Scott Napper, PhD (Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada)

"One focus of our group is to decipher the nature of immune responses by identification of biomarkers and indicators of immune protection. With the support of JPT's high content peptide microarray platform, we created a peptide chip which contains 22.000 individual peptides. This enabled the visualization of the B-cell "signature" in individuals with TB-infection vs. non- infected individuals. In our hands, JPT's peptide microarrays turned out to be very robust tools to identify novel peptide based biomarkers in the context of novel diagnostics and vaccine target identification."
Prof. Markus Maeurer (Karolinska Institute Sweden, Solna, Sweden)

PepSpots™ Peptides on Cellulose

“Our teams at the Vrije Universiteit Brussel deal with a wide variety of projects in different areas of applied biological sciences. For many of them we are in need of peptide related tools and services ranging from peptide libraries and highly purified peptides to peptide arrays. In our search for an integrated and reliable provider we came across JPT. Meanwhile, we are collaborating with JPT for many years and are very satisfied with the relationship which led to several well received publications. Especially, their unique array technology PepSpots™ helped us to enhance our knowledge on different protein protein interactions such as Chaperone-substrate recognition.”  
Prof. Dr. Joost Schymkowitz (Vrije Universiteit, Brussel, Belgium)

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

Specialty Peptides

"AbD Serotec uses JPT’s custom peptide services for many years to generate large numbers of monoclonal antibodies. With the consistent high quality services, the competent customer support and the stringent QA/QC procedures JPT clearly became our preferred peptide partner."
Dr. Karin Jury (AbD Serotec – A Division of Morphosys, Munich, Germany)

"Our research relies heavily on developing robust high-throughput screens with fluorescent peptides.  We have found that JPT’s are the best on the market because the signal-to-noise ratio is very high, providing the sensitivity we need for the screens. Their peptides always perform well. In addition, the knowledge, wonderful customer support, and fast turnaround time provided by JPT have been invaluable in helping us develop the best peptides for our assays."
Prof. Carla Koehler (UCLA, Los angeles, CA, USA)

Amyloid beta peptides (or Aβ, Abeta, Beta Amyloid)

“Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.  We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.”
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands

Micro-Scale Peptide Sets

"Our group at OHSU has purchased more than 50 000 peptides over the past few years from JPT to support our proteome wide TB epitope discovery program.  We are impressed by the turnaround times and highly competitive pricing structure for such large numbers of peptides and are very satisfied with the responsive and professional service."
Gwendolyn Swarbrick (Oregon Health & Science University, USA)

“Our teams at the Vrije Universiteit Brussel deal with a wide variety of projects in different areas of applied biological sciences. For many of them we are in need of peptide related tools and services ranging from peptide libraries and highly purified peptides to peptide arrays. In our search for an integrated and reliable provider we came across JPT. Meanwhile, we are collaborating with JPT for many years and are very satisfied with the relationship which led to several well received publications. Especially, their unique array technology PepSpots™ helped us to enhance our knowledge on different protein protein interactions such as Chaperone-substrate recognition.”  
Prof. Dr. Joost Schymkowitz (Vrije Universiteit, Brussel, Belgium)

Enzyme Profiling Tools

"With JPT´s peptide microarray platform, high- throughput kinase profiling using small amounts of cell lysate becomes feasible, providing access to the discovery and monitoring of novel biomarkers in Parkinson's Disease. "
Jeremy Nichols, PhD (Parkinsons's Institute, Sunnyvale, CA, USA)

“For several years, my group at the Tumor Biology Center has been using JPT’s Protease Profiling Tools for analyzing the substrate specificity of tumor-associated proteases as well as for identifying cancer specific protease patterns.”
Felix Kratz, Ph.D (Clinic for Tumor Biology, Freiburg, Germany)

“We were very pleased with how easy it was to do the experiment(with Kinase Substrate Sets) using the equipment we had on hand - for example, we just used our 8-channel micropipette to add the enzyme/ATP mix.“
Betty A. Eipper, Ph.D (University of Connecticut, Farmington, CT, USA)

"We have successfully applied JPT's peptide microarrays as a screening tool for potential kinases transfering phosphate to phosphorylation sites identified by mass spectrometry. The triplicate alignment as well as the thorough selection of controls enabled generation of high quality data confirming our in vivo data generated by means of affinity chromatographic procedures."
Dr. Marcelo P. Coba (The Wellcome Trust Sanger Institute, Cambridge, UK)

"JPT’s new extremely high-density histone peptide array is a dramatic leap forward for analysis of the histone code hypothesis. The complete sequence coverage across core histones and histone variants as well as the presence of common and rare histone post-translational modifications – alone and in combination – makes this an unparalleled tool for studying the “writers” and “readers” of the histone code. My laboratory has used these arrays to ask the sequence and PTM dependence of a histone writer enzyme and we have discovered an activity specifying code that will keep us busy for years to come."
David Shechter, PhD, Department of Biochemistry, Albert Einstein College of Medicine,  Yeshiva University, NY, USA

SpikeTides™ Proteotypic Peptides

"My  group studies the proteomic composition of distinct chromatin domains, the mechanisms that operate to maintain the composition of histone modifications and the associated proteins. For precise and accurate identification and quantification of histone peptides that carry multiple post-translational modifications directly from biological samples JPT's SpikeTides™_TQL peptide standards proved to be of excellent value for our research in various projects."   
Prof. Dr. Axel Imhof, Adolf-Butenandt Institute, University of Munich, Germany

"My unit at the Banting and Best Department of Medical Research, University of Toronto Centre for Cellular and Biomolecular Research (CCBR) works on the systematic identification and quantification of proteins and protein complexes on a global level. In addition we have started to perform targeted proteomics to study protein regulation within pathways, e.g. signaling pathways during stem cell fate decision. For this we used JPT's various SpikeTides™ peptide products to build LC-MRM assays in a fast and cost efficient manner. More recently we also found new ways of using low cost SpikeTides™ as quantitative peptide standards in order to quantify protein targets more accurately. We are currently in the process of validating this technology for the accurate quantification of various predicted microRNA targets."
Prof. Andrew Emili (Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Canada)

"We at the ETH successfully apply JPT’s unpurified isotope- and non-labeled peptide libraries for proteome-wide SRM assays allowing us to identify and quantify proteins spanning a broad range of abundances, including proteins not previously detectable. With the ability to produce large numbers of affordable small scale proteotypic peptides we envision for the first time the development of assays for the quantitative analysis for any proteinof interest and covering of whole proteomes."
Paola Picotti, PhD (Institute of Molecular Systems Biology, ETH Zürich, Switzerland)

SpikeMix™

"As Director of the Protein Profiling at Yale Keck Biotechnology Resource Facility, I coordinated a collaboration between the Association of Biomolecular Resource Facilities (ABRF) standard proteomic research group (sPRG) and JPT Peptide Technologies to develop the ABRF cross-species SpikeMix™ Peptide Pool. The joint development turned out to be an extraordinary effective endeavor and the resulting product was qualified in more than 52 proteomics labs around the globe. I was impressed by JPT's scientific and technological capabilities as well as their enthusiasm to drive the project forward."
Christopher M. Colangelo, Director of Protein Profiling at Keck Biotechnology Resource Facility, Yale University, USA

"Our research at Stanford University seeks to discover unconventional translation products, and proteins made by unsequenced organisms; to characterize a wide array of protein post-translational modifications; and to perform peptide antigen binding assays.  On all of these fronts, we are in need of high quality peptide standards for assay development and protein quantification. The successful collaboration with the team at JPT Peptide Technologies and their wide range of products has been a critical factor for advancing my group’s research."
Joshua E. Elias, Ph.D., Chemical & Systems Biology, Stanford University School of Medicine, Clark Center, Stanford, CA 

BioTides™ Biotinylated Peptides

"Our group at OHSU has purchased more than 50 000 peptides over the past few years from JPT to support our proteome wide TB epitope discovery program.  We are impressed by the turnaround times and highly competitive pricing structure for such large numbers of peptides and are very satisfied with the responsive and professional service."
Gwendolyn Swarbrick (Oregon Health & Science University, USA)

Peptide Conjugates

"AbD Serotec uses JPT’s custom peptide services for many years to generate large numbers of monoclonal antibodies. With the consistent high quality services, the competent customer support and the stringent QA/QC procedures JPT clearly became our preferred peptide partner."
Dr. Karin Jury, AbD Serotec – A Division of Morphosys, Munich, Germany

Stay in touch and be the first to receive the latest news!